BC Extra | Jul 11, 2017
Financial News

Evelo raises $50M in series B round

Evelo Biosciences Inc. (Cambridge, Mass.) raised $50 million in a series B round from Flagship Pioneering; GV, the venture arm of Alphabet Inc. (NASDAQ:GOOG); Celgene Corp. (NASDAQ:CELG); the Mayo Clinic ; and Alexandria Venture Investments....
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; cancer In vitro and mouse studies suggest class IIa-selective HDAC inhibitors could help treat cancer. In a mouse model of breast cancer, the class IIa HDAC inhibitor TMP195 increased macrophage infiltration in...
BC Innovations | Apr 13, 2017
Translation in Brief

Eating cancer

With immuno-oncology companies increasingly looking beyond T cells to other immune cell types that could drive an antitumor response, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has hit on a new strategy for enlisting macrophages. Although the cells...
BC Innovations | Apr 4, 2013
Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
BC Innovations | Apr 4, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Trifluoromethyloxadiazole (TFMO)-containing compounds to identify class IIa histone deacetylase (HDAC) inhibitors TFMO-containing compounds could be used as research compounds to guide...
BC Innovations | Aug 11, 2011
Targets & Mechanisms

Gutsy call on Th17 cells

Researchers at the Yale School of Medicine have shown that the small intestine regulates proinflammatory T helper type 17 cells via two mechanisms, including one that leads to an immunosuppressive, regulatory phenotype. 1 The findings...
BC Innovations | Jun 9, 2011
Cover Story

Raising a Treg cell army

Despite promising preclinical findings that raising levels of T reg cells might have utility against autoimmune disease, obtaining enough of the rare cells from humans has been a major translational obstacle. Now, British and American...
BC Innovations | Apr 28, 2011
Cover Story

Immune dampening at the source

Two U.S. academic groups have separately identified small molecule RAR-related orphan receptor inhibitors that block production of proinflammatory T helper type 17 cells and decrease disease severity in a mouse model of multiple sclerosis. 1,2...
BioCentury | Dec 21, 2009
Regulation

Overall Survival was not enough

A 12-1 vote by FDA's Oncologic Drugs Advisory Committee against approving Tarceva erlotinib for first-line maintenance therapy in non-small cell lung cancer was hardly the first time an advisory panel has snubbed a proposed treatment...
BC Week In Review | May 25, 2009
Company News

GlaxoSmithKline autoimmune news

GlaxoSmithKline created a research unit in Cambridge, Mass., to discover small molecule drug candidates targeting regulatory T cells and T helper type 17 (Th17) effector cells for autoimmune diseases. The pharma plans to spin out...
Items per page:
1 - 10 of 13
BC Extra | Jul 11, 2017
Financial News

Evelo raises $50M in series B round

Evelo Biosciences Inc. (Cambridge, Mass.) raised $50 million in a series B round from Flagship Pioneering; GV, the venture arm of Alphabet Inc. (NASDAQ:GOOG); Celgene Corp. (NASDAQ:CELG); the Mayo Clinic ; and Alexandria Venture Investments....
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; cancer In vitro and mouse studies suggest class IIa-selective HDAC inhibitors could help treat cancer. In a mouse model of breast cancer, the class IIa HDAC inhibitor TMP195 increased macrophage infiltration in...
BC Innovations | Apr 13, 2017
Translation in Brief

Eating cancer

With immuno-oncology companies increasingly looking beyond T cells to other immune cell types that could drive an antitumor response, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has hit on a new strategy for enlisting macrophages. Although the cells...
BC Innovations | Apr 4, 2013
Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
BC Innovations | Apr 4, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Trifluoromethyloxadiazole (TFMO)-containing compounds to identify class IIa histone deacetylase (HDAC) inhibitors TFMO-containing compounds could be used as research compounds to guide...
BC Innovations | Aug 11, 2011
Targets & Mechanisms

Gutsy call on Th17 cells

Researchers at the Yale School of Medicine have shown that the small intestine regulates proinflammatory T helper type 17 cells via two mechanisms, including one that leads to an immunosuppressive, regulatory phenotype. 1 The findings...
BC Innovations | Jun 9, 2011
Cover Story

Raising a Treg cell army

Despite promising preclinical findings that raising levels of T reg cells might have utility against autoimmune disease, obtaining enough of the rare cells from humans has been a major translational obstacle. Now, British and American...
BC Innovations | Apr 28, 2011
Cover Story

Immune dampening at the source

Two U.S. academic groups have separately identified small molecule RAR-related orphan receptor inhibitors that block production of proinflammatory T helper type 17 cells and decrease disease severity in a mouse model of multiple sclerosis. 1,2...
BioCentury | Dec 21, 2009
Regulation

Overall Survival was not enough

A 12-1 vote by FDA's Oncologic Drugs Advisory Committee against approving Tarceva erlotinib for first-line maintenance therapy in non-small cell lung cancer was hardly the first time an advisory panel has snubbed a proposed treatment...
BC Week In Review | May 25, 2009
Company News

GlaxoSmithKline autoimmune news

GlaxoSmithKline created a research unit in Cambridge, Mass., to discover small molecule drug candidates targeting regulatory T cells and T helper type 17 (Th17) effector cells for autoimmune diseases. The pharma plans to spin out...
Items per page:
1 - 10 of 13